Generic Natrecor Availability
NATRECOR (nesiritide recombinant - for solution;intravenous)
Manufacturer: SCIOS LLC
Approval date: August 10, 2001
Strength(s): 1.5MG/VIAL [RLD]
Has a generic version of Natrecor been approved?
No. There is currently no therapeutically equivalent version of Natrecor available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Natrecor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Recombinant techniques for production of novel natriuretic and vasodilator peptides
Issued: May 19, 1992
Inventor(s): Seilhamer; Jeffrey J. & Lewicki; John A. & Scarborough; Robert M. & Porter; J. Gordon
Assignee(s): California Biotechnology Inc.
The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically. The invention peptides have the formula: ##STR1## wherein R.sup.1 is selected from the group consisting of: ##STR2## or a 10- to 109-amino acid sequence shown as the native upstream sequence for porcine, canine or human NP in FIG. 6, or a composite thereof; R.sup.2 is (OH), NH.sub.2, or NR'R" wherein R' and R" are independently lower alkyl (1-4C) or is ##STR3## or the amides (NH.sub.2 or NR'R") thereof, with the proviso that if formula (1) is EQU R.sup.1 -Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg- Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-R.sup.2 and R.sup.1 is Asp-Ser-Gly-, R.sup.2 cannot be Asn-Val-Leu-Arg-Arg-Tyr. The peptides of the invention can be formulated into pharmaceutical compositions and used to treat conditions associated with high extracellular fluid levels, especially congestive heart failure.Patent expiration dates:
- May 19, 2014✓✓✓
- May 19, 2014
- Natrecor Consumer Information (Drugs.com)
- Natrecor Consumer Information (Wolters Kluwer)
- Natrecor Consumer Information (Cerner Multum)
- Natrecor Advanced Consumer Information (Micromedex®)
- Natrecor AHFS DI Monographs (ASHP)
- Nesiritide Consumer Information (Wolters Kluwer)
- Nesiritide Consumer Information (Cerner Multum)
- Nesiritide Intravenous Advanced Consumer Information (Micromedex®)
- Nesiritide AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|